These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

858 related items for PubMed ID: 27548616

  • 1. Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors.
    Thokala R, Olivares S, Mi T, Maiti S, Deniger D, Huls H, Torikai H, Singh H, Champlin RE, Laskowski T, McNamara G, Cooper LJ.
    PLoS One; 2016; 11(8):e0159477. PubMed ID: 27548616
    [Abstract] [Full Text] [Related]

  • 2. Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia.
    Tasian SK, Kenderian SS, Shen F, Ruella M, Shestova O, Kozlowski M, Li Y, Schrank-Hacker A, Morrissette JJD, Carroll M, June CH, Grupp SA, Gill S.
    Blood; 2017 Apr 27; 129(17):2395-2407. PubMed ID: 28246194
    [Abstract] [Full Text] [Related]

  • 3. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia.
    Mardiros A, Dos Santos C, McDonald T, Brown CE, Wang X, Budde LE, Hoffman L, Aguilar B, Chang WC, Bretzlaff W, Chang B, Jonnalagadda M, Starr R, Ostberg JR, Jensen MC, Bhatia R, Forman SJ.
    Blood; 2013 Oct 31; 122(18):3138-48. PubMed ID: 24030378
    [Abstract] [Full Text] [Related]

  • 4. Chimeric Antigen Receptors Incorporating D Domains Targeting CD123 Direct Potent Mono- and Bi-specific Antitumor Activity of T Cells.
    Qin H, Edwards JP, Zaritskaya L, Gupta A, Mu CJ, Fry TJ, Hilbert DM, LaFleur DW.
    Mol Ther; 2019 Jul 03; 27(7):1262-1274. PubMed ID: 31043341
    [Abstract] [Full Text] [Related]

  • 5. Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved Sleeping Beauty transposon platform.
    Magnani CF, Turazzi N, Benedicenti F, Calabria A, Tenderini E, Tettamanti S, Giordano Attianese GM, Cooper LJ, Aiuti A, Montini E, Biondi A, Biagi E.
    Oncotarget; 2016 Aug 09; 7(32):51581-51597. PubMed ID: 27323395
    [Abstract] [Full Text] [Related]

  • 6. Improved Activity against Acute Myeloid Leukemia with Chimeric Antigen Receptor (CAR)-NK-92 Cells Designed to Target CD123.
    Morgan MA, Kloos A, Lenz D, Kattre N, Nowak J, Bentele M, Keisker M, Dahlke J, Zimmermann K, Sauer M, Heuser M, Schambach A.
    Viruses; 2021 Jul 14; 13(7):. PubMed ID: 34372571
    [Abstract] [Full Text] [Related]

  • 7. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.
    Milone MC, Fish JD, Carpenito C, Carroll RG, Binder GK, Teachey D, Samanta M, Lakhal M, Gloss B, Danet-Desnoyers G, Campana D, Riley JL, Grupp SA, June CH.
    Mol Ther; 2009 Aug 14; 17(8):1453-64. PubMed ID: 19384291
    [Abstract] [Full Text] [Related]

  • 8. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities.
    Christodoulou I, Ho WJ, Marple A, Ravich JW, Tam A, Rahnama R, Fearnow A, Rietberg C, Yanik S, Solomou EE, Varadhan R, Koldobskiy MA, Bonifant CL.
    J Immunother Cancer; 2021 Dec 14; 9(12):. PubMed ID: 34896980
    [Abstract] [Full Text] [Related]

  • 9. Balance of Anti-CD123 Chimeric Antigen Receptor Binding Affinity and Density for the Targeting of Acute Myeloid Leukemia.
    Arcangeli S, Rotiroti MC, Bardelli M, Simonelli L, Magnani CF, Biondi A, Biagi E, Tettamanti S, Varani L.
    Mol Ther; 2017 Aug 02; 25(8):1933-1945. PubMed ID: 28479045
    [Abstract] [Full Text] [Related]

  • 10. Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains.
    Alabanza L, Pegues M, Geldres C, Shi V, Wiltzius JJW, Sievers SA, Yang S, Kochenderfer JN.
    Mol Ther; 2017 Nov 01; 25(11):2452-2465. PubMed ID: 28807568
    [Abstract] [Full Text] [Related]

  • 11. CD123 redirected multiple virus-specific T cells for acute myeloid leukemia.
    Zhou L, Liu X, Wang X, Sun Z, Song XT.
    Leuk Res; 2016 Feb 01; 41():76-84. PubMed ID: 26740053
    [Abstract] [Full Text] [Related]

  • 12. Programmed cell death protein 1 activation preferentially inhibits CD28.CAR-T cells.
    Zolov SN, Rietberg SP, Bonifant CL.
    Cytotherapy; 2018 Oct 01; 20(10):1259-1266. PubMed ID: 30309710
    [Abstract] [Full Text] [Related]

  • 13. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells.
    Gill S, Tasian SK, Ruella M, Shestova O, Li Y, Porter DL, Carroll M, Danet-Desnoyers G, Scholler J, Grupp SA, June CH, Kalos M.
    Blood; 2014 Apr 10; 123(15):2343-54. PubMed ID: 24596416
    [Abstract] [Full Text] [Related]

  • 14. Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma.
    Oelsner S, Friede ME, Zhang C, Wagner J, Badura S, Bader P, Ullrich E, Ottmann OG, Klingemann H, Tonn T, Wels WS.
    Cytotherapy; 2017 Feb 10; 19(2):235-249. PubMed ID: 27887866
    [Abstract] [Full Text] [Related]

  • 15. Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts.
    Cartellieri M, Feldmann A, Koristka S, Arndt C, Loff S, Ehninger A, von Bonin M, Bejestani EP, Ehninger G, Bachmann MP.
    Blood Cancer J; 2016 Aug 12; 6(8):e458. PubMed ID: 27518241
    [Abstract] [Full Text] [Related]

  • 16. CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia.
    Bonifant CL, Szoor A, Torres D, Joseph N, Velasquez MP, Iwahori K, Gaikwad A, Nguyen P, Arber C, Song XT, Redell M, Gottschalk S.
    Mol Ther; 2016 Sep 29; 24(9):1615-26. PubMed ID: 27401038
    [Abstract] [Full Text] [Related]

  • 17. Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor.
    Tettamanti S, Marin V, Pizzitola I, Magnani CF, Giordano Attianese GM, Cribioli E, Maltese F, Galimberti S, Lopez AF, Biondi A, Bonnet D, Biagi E.
    Br J Haematol; 2013 May 29; 161(3):389-401. PubMed ID: 23432359
    [Abstract] [Full Text] [Related]

  • 18. Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia.
    Laborda E, Mazagova M, Shao S, Wang X, Quirino H, Woods AK, Hampton EN, Rodgers DT, Kim CH, Schultz PG, Young TS.
    Int J Mol Sci; 2017 Oct 27; 18(11):. PubMed ID: 29077054
    [Abstract] [Full Text] [Related]

  • 19. AntiCD3Fv fused to human interleukin-3 deletion variant redirected T cells against human acute myeloid leukemic stem cells.
    Fan D, Li Z, Zhang X, Yang Y, Yuan X, Zhang X, Yang M, Zhang Y, Xiong D.
    J Hematol Oncol; 2015 Feb 28; 8():18. PubMed ID: 25879549
    [Abstract] [Full Text] [Related]

  • 20. In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia.
    Minagawa K, Jamil MO, Al-Obaidi M, Pereboeva L, Salzman D, Erba HP, Lamb LS, Bhatia R, Mineishi S, Di Stasi A.
    PLoS One; 2016 Feb 28; 11(12):e0166891. PubMed ID: 27907031
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.